<div id="readability-page-1"><p>In a report released today, Etzer Darout from Barclays maintained a Buy rating on MacroGenics, with a price target of <span id="expert-recommendation-target">$6.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Darout covers the Healthcare sector, focusing on stocks such as Incyte, Legend Biotech, and Oruka Therapeutics. According to TipRanks, Darout has an average return of <span>26.4%</span> and a 56.04% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on MacroGenics is a Moderate Buy with an average price target of $6.33.</p></div>

MGNX

IBBQ

<p>Barclays analyst Etzer Darout has reaffirmed a Buy rating on MacroGenics (MGNX) with a price target of $6.00. The analyst focuses on the Healthcare sector and has an average return of 26.4% with a 56.04% success rate on stock recommendations. The current consensus on MacroGenics is a Moderate Buy, with an average price target of $6.33.</p>

Tip Ranks

Macrogenics

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VG Health

iShares US Pharma

iShares Biotechnology ETF

Health Care Select Sector SPDR

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Barclays

Incyte

Legend Biotech

Oruka Therapeutics

Barclays Reaffirms Their Buy Rating on MacroGenics (MGNX)